The European Union has approved Lecanemab, a groundbreaking drug developed by Biogen to slow down the progression of Alzheimer’s disease. Manufactured in Luterbach, Switzerland, it targets harmful amyloid proteins in the brain, improving cognitive function in early-stage patients. Despite some manageable side effects, experts like Prof. Bogdan Draganski assert its effectiveness and potential to enhance quality of life. Initially rejected in July, the EU’s change of heart was influenced by data from countries where the drug has already been authorized, highlighting the growing confidence in its benefits.